Description:
Reference #: 01642
The University of South Carolina is offering licensing opportunities for Trigonelline mitigates cardiomyopathy caused by SARS-CoV-2 spike protein under obesity.
Background:
Today, the spread of Coronavirus Disease 2019 (COVID-19) continues, and while millions of patients have recovered, a significant number experience prolonged illness known as long COVID. This condition poses a major challenge for doctors, particularly as many long COVID patients develop heart problems.
Invention Description:
We can show that spike proteins from the SARS-CoV-2 can damage a place in heart cells for energy production. In this invention, we show that trigonelline is a natural substance that can protect the heart from SARS-CoV-2-caused damage in obese patients.
Potential Applications:
This innovation addresses the problem of cardiovascular complications in patients affected by SARS-CoV-2, both in acute COVID-19 cases and in patients with post-acute sequelae of SARS-CoV-2 infection (PACS). By utilizing trigonelline, this invention aims to mitigate and protect against the detrimental impact on the heart caused by the virus, offering potential relief and improved outcomes for these patients.
Advantages and Benefits:
Trigonelline offers several advantages as a potential treatment for cardiovascular complications in acute COVID-19 and PACS patients. Its natural origin and presence in commonly consumed plants like coffee beans ensure a well-tested and approved safety profile. The ease of availability and formulation make it readily accessible for patients. Moreover, trigonelline's ability to mitigate mitochondrial dysfunction and cell death induced by SARS-CoV-2 in combination with LDL-c makes it a targeted and promising therapeutic option for addressing cardiovascular complications in these patient populations.